Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 with or without empagliflozin for portal hypertension in compensated cirrhosis
NL-OMON53952Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avenciguat and empagliflozin in Portal Hypertension (PH) and Cirrhosis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage change in hepatic venous pressure gradient from baseline at 8 weeks. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
avenciguatempagliflozin
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on NL-OMON53952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53952.